Groundbreaking Late-Breaking Science

Scientific Sessions is known for presenting  groundbreaking results in cardiovascular science and health care, and this year is no exception. Be sure to add these Late-Breaking Science sessions to your AHA19 itinerary.

Late-Breaking Science I: Outside the Box: New Approaches to CVD Risk Reduction

Saturday, Nov. 16, 10:45 a.m.-Noon

  • DAPA-HF: Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF): Results in Nondiabetic Patients
  • ORION-10: Phase 3 Trial Results: Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol
  • COLCOT: The Colchicine Cardiovascular Outcomes Trial in Coronary Disease
  • BETonMACE: Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes

Late-Breaking Science II: Results for the Ischemia Trials: To Intervene or Not to Intervene

Saturday, Nov. 16, 2-3:15 p.m.

  • ISCHEMIA: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes
  • ISCHEMIA: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Quality of Life Outcomes
  • ISCHEMIA-CKD: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches in Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes

Late Breaking Science III: Controversies in Contemporary Management of AS

Saturday, Nov. 16, 5:30-6:45 p.m.

  • GALILEO: Primary Results: Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy Versus an Antiplatelet-Based Strategy After Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes
  • GALILEO-4D: Randomized Clinical Trial Comparing a Rivaroxaban-Based Strategy with an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves
  • Balloon-Expandable Versus Self-expandable TAVR on Paravalvular Regurgitation and 2-year Mortality: A Propensity-Matched Comparison From the France-TAVI Registry
  • RECOVERY: Early Surgery Versus Conventional Management for Asymptomatic Severe Aortic Stenosis

Late-Breaking Science IV: State-of-the-Art Interventional Management for ACS Patients

Sunday, Nov. 17, 9-10:15 a.m.

  • TWILIGHT-ACS:- Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention for Acute Coronary Syndrome
  • COLCHICINE-PCI: Peri-procedural Colchicine in Percutaneous Coronary Intervention
  • OCT COMPLETE: Non-culprit Lesion Plaque Morphology in Patients With ST-Segment Elevation Myocardial Infarction: Substudy From the Complete Trial Using Optical Coherence Tomography
  • COACT: One-Year Outcomes of Coronary Angiography After Cardiac Arrest
  • Comparative Effectiveness and Costs of Impella Versus Intra-Aortic Balloon Pump in the United States
  • Mortality and Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Impella® Versus Intra-Aortic Balloon Pump

Late-Breaking Science V: Challenges in Heart Failure Management

Sunday, Nov. 17, 10:45 a.m.-Noon

  • FUEL: Longitudinal Results From the Pediatric Heart Network: Effect of Udenafil on Exercise Performance After Fontan
  • DAPA-HF: Effect of Treatment Based on Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
  • DAPA-HF: Effect of Treatment Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
  • PARAGON-HF: Effects of Sacubitril/valsartan in Women Compared to Men With Heart Failure and Preserved Ejection Fraction
  • PARAGON-HF Secondary Analysis: Effect of Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Late-Breaking Science VI: New Frontiers in Lipid Therapy

Monday, Nov. 18, 9-10:15 a.m.

  • EVAPORATE: Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients on Statin Therapy With Elevated Triglycerides (200-499mg/dl)
  • ORION-9: Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia
  • RNA Interference Targeting Apolipoprotein C-III Results in Healthy Adults, Those Having Severe Hypertriglyceridemia and in Familial Chylomicronemia Syndrome
  • Results Using RNA Interference to Target Hepatic Angiopoietin-like Protein 3 in Prolonging Reductions in Plasma Triglycerides and LDL-C in Humans
  • Treat Stroke to Target: Benefit of a Target LDL Cholesterol Less Than 70 mg/dl After Ischemic Stroke Due to Atherosclerosis

For more details, visit the Online Program Planner.

Top